QDEL

22.05

-2.48%↓

NERV

3.79

-3.32%↓

LSTA.US

1.99

-5.24%↓

QDEL

22.05

-2.48%↓

NERV

3.79

-3.32%↓

LSTA.US

1.99

-5.24%↓

QDEL

22.05

-2.48%↓

NERV

3.79

-3.32%↓

LSTA.US

1.99

-5.24%↓

QDEL

22.05

-2.48%↓

NERV

3.79

-3.32%↓

LSTA.US

1.99

-5.24%↓

QDEL

22.05

-2.48%↓

NERV

3.79

-3.32%↓

LSTA.US

1.99

-5.24%↓

Search

Laboratorios Farmaceuticos Rovi SA

Închisă

SectorSănătate

58.75 -1.09

Rezumat

Modificarea prețului

24h

Curent

Minim

58.6

Maxim

59.75

Indicatori cheie

By Trading Economics

Venit

3.9M

27M

Vânzări

4.8M

160M

P/E

Medie Sector

24.915

105.69

EPS

0.423

Randament dividend

1.65

Marjă de profit

16.767

Angajați

2,197

EBITDA

4.2M

35M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+36.69% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.65%

2.37%

Statistici piață

By TradingEconomics

Capitalizare de piață

414M

3.2B

Deschiderea anterioară

59.84

Închiderea anterioară

58.75

Sentimentul știrilor

By Acuity

50%

50%

182 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 nov. 2025, 21:55 UTC

Câștiguri

Xero Beats 1st Half Profit Expectations Despite Melio Margin Hit

12 nov. 2025, 21:34 UTC

Câștiguri

Cisco Systems Boosts Fiscal Year Outlook as 1Q Profit, Revenue Rise

12 nov. 2025, 23:44 UTC

Market Talk

Nikkei May Trade in Range Amid Caution Over U.S. Econ -- Market Talk

12 nov. 2025, 23:38 UTC

Market Talk

Gold Steady Ahead of Expected End to U.S. Government Shutdown -- Market Talk

12 nov. 2025, 23:13 UTC

Câștiguri

Samsung Fire & Marine Insurance 3Q Net Profit Largely Met FactSet-Compiled Consensus

12 nov. 2025, 23:13 UTC

Câștiguri

Samsung Fire & Marine Insurance 3Q Net KRW538.50B Vs. Net KRW554.56B >000810.SE

12 nov. 2025, 23:13 UTC

Câștiguri

Samsung Fire & Marine Insurance 3Q Oper Pft KRW664.06B Vs. Pft KRW717.46B >000810.SE

12 nov. 2025, 23:13 UTC

Câștiguri

Samsung Fire & Marine Insurance 3Q Rev KRW5.732T Vs. KRW5.326T >000810.SE

12 nov. 2025, 22:30 UTC

Market Talk
Câștiguri

Firefly Aerospace Sets Plan for Next Launch After Explosion -- Market Talk

12 nov. 2025, 22:18 UTC

Câștiguri

Cisco Systems Boosts Outlook on AI-Driven Demand -- Update

12 nov. 2025, 22:12 UTC

Market Talk

Bank of Canada Rate Hikes Could Start in 2H 2026 -- Market Talk

12 nov. 2025, 22:05 UTC

Câștiguri

Pan American Silver: Campbell Succeeded Steve Busby >PAAS

12 nov. 2025, 22:04 UTC

Câștiguri

Pan American Silver Named Scott Campbell as Operating Chief on Oct. 20

12 nov. 2025, 22:04 UTC

Câștiguri

Pan American Silver 3Q Adj EPS 48c >PAAS

12 nov. 2025, 22:04 UTC

Câștiguri

Pan American Silver 3Q Rev $884.4M >PAAS

12 nov. 2025, 22:04 UTC

Câștiguri

Pan American Silver 3Q EPS 45c >PAAS

12 nov. 2025, 22:03 UTC

Câștiguri

Manulife Financial: 3Q Book Value Per Common Shr C$26.07 >MFC.T

12 nov. 2025, 22:02 UTC

Câștiguri

Manulife Financial 3Q Net C$1.8B >MFC

12 nov. 2025, 22:02 UTC

Câștiguri

Manulife Financial 3Q Adj EPS C$1.16 >MFC

12 nov. 2025, 22:02 UTC

Câștiguri

Manulife Financial 3Q EPS C$1.02 >MFC

12 nov. 2025, 21:53 UTC

Achiziții, Fuziuni, Preluări

BlueScope Steel: Sale Strengthens Focus on Own Growth Investments

12 nov. 2025, 21:53 UTC

Achiziții, Fuziuni, Preluări

BlueScope Steel Says Deal Subject to Indian Regulatory Approvals

12 nov. 2025, 21:53 UTC

Achiziții, Fuziuni, Preluări

BlueScope Steel Estimates Net Profit After Tax on Sale of A$70 Million

12 nov. 2025, 21:53 UTC

Achiziții, Fuziuni, Preluări

BlueScope Steel Expects Net Proceeds After Taxes, Fees of A$179 Million in 2H FY26

12 nov. 2025, 21:52 UTC

Achiziții, Fuziuni, Preluări

BlueScope Steel: Tata BlueScope Steel JV a Provider of Coated, Painted Steel Products in India

12 nov. 2025, 21:51 UTC

Achiziții, Fuziuni, Preluări

BlueScope Steel Agrees to Sell 50% Stake in Tata BlueScope Steel Joint Venture to Tata Steel

12 nov. 2025, 21:50 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

12 nov. 2025, 21:49 UTC

Câștiguri

Cisco Stock Climbs as Earnings Beat Expectations Amid Strong AI Demand -- Barrons.com

12 nov. 2025, 21:48 UTC

Câștiguri

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares. -- Barrons.com

12 nov. 2025, 21:40 UTC

Câștiguri

Xero Beats 1H Profit Expectations Despite Melio Margin Hit

Comparație

Modificare preț

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

36.69% sus

Prognoză pe 12 luni

Medie 80.85 EUR  36.69%

Maxim 90 EUR

Minim 71.7 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

51.1 / N/ASuport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

182 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat